MS
NBIX icon

Maven Securities’s Neurocrine Biosciences NBIX Stock Holding History

Maven Securities’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-10,890
Closed -$979K – 395
2019
Q3 		$979K Buy
+10,890
New +$1.02M 0.31% 85
2018
Q4 		– Sell
-6,672
Closed -$822K – 145
2018
Q3 		$822K Buy
+6,672
New +$757K 0.3% 78
2017
Q1 		– Sell
-567
Closed -$21K – 59
2016
Q4 		$21K Buy
+567
New +$25.7K 0.02% 42

Other funds holding NBIX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Maven Securities's NBIX Position: Q4 2019 in Review

Maven Securities sold out of Neurocrine Biosciences (NBIX) in Q4 2019, closing a stake of 10,890 shares — an estimated $979K sold.

Maven Securities first reported a position in NBIX in Q4 2016 and held it in 3 quarters. The position peaked at $979K in Q3 2019. 391 funds tracked by Wall St. Rank hold NBIX as of Q4 2019.

  • Maven Securities reported no remaining Neurocrine Biosciences position as of Q4 2019 after selling out during the quarter.
  • Maven Securities sold 10,890 Neurocrine Biosciences shares in Q4 2019, an estimated $979K.
  • Maven Securities first reported a position in Neurocrine Biosciences in Q4 2016 and held it in 3 quarters.
  • Maven Securities's Neurocrine Biosciences position peaked at $979K in Q3 2019.
  • 391 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2019.

Based on Maven Securities's 13F filing for Q4 2019, filed 14 Feb 2020.